2026

Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter Analysis
Al-Bazaz M, Alsdorf W, Leypoldt L, Sonnemann P, Schaefers C, Artzenroth J, Harzer M, Kamili A, Bartke L, Cords L, Vorwerk J, Leitner T, Maulhardt M, Brinkert K, Brioli A, Richardson T, Holtick U, Hillmann S, Salwender H, Khandanpour C, Bokemeyer C, Weisel K, Kosch R
AM J HEMATOL. 2026 [Epub ahead of print].

Hepatitis E virus infections in people with multiple myeloma an emerging challenge in the era of immunotherapeutic approaches
Al-Bazaz M, Pischke S, Alsdorf W, Sonnemann P, Cichutek S, Wiesch J, Schaefers C, Artzenroth J, Leypoldt L, Kamili A, Bokemeyer C, Weisel K, Kosch R
HAEMATOLOGICA. 2026;111(3):1017-1028.

2025

Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement
Steinhardt M, Schaefers C, Leypoldt L, Blau I, Harzer M, Zhou X, Riedhammer C, Kamili A, Kosch R, Topp L, Molwitz I, Gross-Fengels N, Melzer Y, Artzenroth J, Al-Bazaz M, Alsdorf W, Topp M, Duell J, Mersi J, Waldschmidt J, Bokemeyer C, Einsele H, Kortüm K, Weisel K, Rasche L
BLOOD CANCER J. 2025;15(1):126.

Correction: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement
Steinhardt M, Schaefers C, Leypoldt L, Blau I, Harzer M, Zhou X, Riedhammer C, Kamili A, Kosch R, Topp L, Molwitz I, Gross-Fengels N, Melzer Y, Artzenroth J, Al-Bazaz M, Alsdorf W, Topp M, Duell J, Mersi J, Waldschmidt J, Bokemeyer C, Einsele H, Kortüm K, Weisel K, Rasche L
BLOOD CANCER J. 2025;15(1):.

2023

Combining Poly-(ARD-Ribose) Polymerase and Programmed Cell Death Protein 1 Inhibition in a Patient with Esophagogastric Adenocarcinoma
Artzenroth J, Tintelnot J, Haag G, Gökkurt E, Steffens J, Stein A
ONCOL RES TREAT. 2023;46(7-8):320-325.

Letzte Aktualisierung aus dem FIS: 06.04.2026 - 00:38 Uhr